EUCTR2008-006977-34-FR进行中（未招募）1 期
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- •1.Male or female patients 18 years or older
- •2.Have one of the following diagnoses:
- •a) Acute myelogenous leukemia (as defined in WHO criteria (28)) with > 10% bone marrow or peripheral blood blasts. This includes leukemia secondary to prior chemotherapy or resulting from an antecedent hematologic disorder, who have failed to achieve CR or relapse after prior therapy and who are not candidates for potentially curative treatment options. Patients who are over age 60 and have not received prior therapy are also eligible, if they are not candidates for standard induction chemotherapy. Patients with acute promyelocytic leukemia (APL) are not eligible.
- •b) High-grade MDS, defined by all the following features: IPSS Intermediate-2 or High Risk; > 10% blasts on bone marrow examination; treatment failure from, or not candidates for, standard therapies including demethylating agents, eg azacytidine or
- •decitabine.
- •3.Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •4.Female patients must meet one of the following:
- •Postmenopausal for at least one year before the screening visit, or
- •Surgically sterile, or
- •If they are of childbearing potential, agree to practice two effective methods of contraception from the time of signing of the informed consent form through one month after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
- •5.Male patients, even if surgically sterilized (ie, status post-vasectomy) must agree to the following:
- •Practice effective barrier contraception during the entire study treatment period and through one month after the last dose of study drug, or completely abstain from heterosexual intercourse.
- •6.Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •7.Patients who are on hydroxyurea may be included in the study and may continue on hydroxyurea while participating in this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting any of the following exclusion criteria are not to be enrolled in the study.
- •1.Pregnant or lactating females
- •2.Known human immunodeficiency virus (HIV) positive or AIDS-related illness
- •3.Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol
- •4.Total bilirubin > 1.5 x the upper limit of normal (ULN)
- •5.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 x the ULN. AST, ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to their underlying hematological disorder.
- •6.Calculated creatinine clearance < 30 mL/minute (Cockcroft-Gault formula in Section 14.2 of the protocol)
- •7.Systemic antineoplastic therapy, including radiotherapy within 14 days preceding the first dose of study drug treatment, except for hydroxyurea
- •8.Myocardial infarction within 6 months of enrollment or current history of New York Heart Association (NYHA) Class III or IV heart failure (see Section 14.4 of the protocol), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
- •9.Major surgery within 14 days prior to the first dose of study treatment
- •10.Clinically uncontrolled central nervous system (CNS) involvement. Patients who have a history of CNS involvement, but no evidence of active CNS disease, are not excluded.
- •11.Inability to swallow capsules, or inability or unwillingness to avoid taking anything by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose of MLN8237
- •12.History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaPlatinum-refractory and platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomaMedDRA version: 11.1Level: LLTClassification code 10033131Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10016180Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10052171Term: <Manually entered code. Term in E.1.1>EUCTR2008-006979-72-PLMillennium Pharmaceuticals, Inc56
进行中（未招募）
1 期
A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaPlatinum-refractory and platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomaMedDRA version: 11.1Level: LLTClassification code 10033131Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10016180Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10052171Term: <Manually entered code. Term in E.1.1>EUCTR2008-006979-72-FRMillennium Pharmaceuticals, Inc31
已完成
2 期
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic SyndromeAcute Myelogenous LeukemiaHigh-Grade Myelodysplastic SyndromeNCT00830518Millennium Pharmaceuticals, Inc.57
进行中（未招募）
1 期
A study of MLN8237 in patients with Ovarian or Breast Cancer to find the highest safe dose of MLN8237 given in combination with Paclitaxel,followed by further investigation of that dose in cancers of the ovary,fallopian tube or peritoneum to assess the efficacy of MLN8237 pluspaclitaxel compared to paclitaxel alone.EUCTR2009-011428-79-PLMillennium Pharmaceuticals, Inc191
进行中（未招募）
不适用
A study on the effects of adding MLN8237 with Rituximab and Vincristine in patients with B-cell lymphoma treated who have failed previous treatments for the disease.EUCTR2011-000609-32-ESMillennium Pharmaceuticals, Inc100